WO2010049678A3 - Traitement de maladies utilisant de l’énergie - Google Patents

Traitement de maladies utilisant de l’énergie Download PDF

Info

Publication number
WO2010049678A3
WO2010049678A3 PCT/GB2009/002554 GB2009002554W WO2010049678A3 WO 2010049678 A3 WO2010049678 A3 WO 2010049678A3 GB 2009002554 W GB2009002554 W GB 2009002554W WO 2010049678 A3 WO2010049678 A3 WO 2010049678A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
energy utilization
diabetes
diseases
utilization diseases
Prior art date
Application number
PCT/GB2009/002554
Other languages
English (en)
Other versions
WO2010049678A2 (fr
Inventor
Francis Xavier Wilson
Robert James Nash
Graeme Horne
Richard Storer
Jonathan Mark Tinsley
Alan Geoffrey Roach
Original Assignee
Summit Corporation Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0819941A external-priority patent/GB0819941D0/en
Priority claimed from GB0906161A external-priority patent/GB0906161D0/en
Priority claimed from GB0908702A external-priority patent/GB0908702D0/en
Priority claimed from GB0914471A external-priority patent/GB0914471D0/en
Application filed by Summit Corporation Plc filed Critical Summit Corporation Plc
Publication of WO2010049678A2 publication Critical patent/WO2010049678A2/fr
Publication of WO2010049678A3 publication Critical patent/WO2010049678A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L’invention concerne des composés variés, en particulier des immunosucres, pour traiter des maladies utilisant de l’énergie, en particulier le diabète (le diabète de type 1, le diabète de type 2 et la résistance à l’insuline), et le syndrome métabolique (une maladie ou un trouble quelconque associé audit syndrome, par exemple l’obésité abdominale et des niveaux élevés de triglysérides),
PCT/GB2009/002554 2008-10-31 2009-10-27 Traitement de maladies utilisant de l’énergie WO2010049678A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0819941A GB0819941D0 (en) 2008-10-31 2008-10-31 Treatment of energy utilization diseases
GB0819941.6 2008-10-31
GB0906161A GB0906161D0 (en) 2009-04-09 2009-04-09 Treatment for energy utilization diseases
GB0906161.5 2009-04-09
GB0908702A GB0908702D0 (en) 2009-05-20 2009-05-20 Treatment of energy utilization diseases
GB0908702.4 2009-05-20
GB0914471A GB0914471D0 (en) 2009-08-19 2009-08-19 Treatment of energy utilization diseases
GB0914471.8 2009-08-19

Publications (2)

Publication Number Publication Date
WO2010049678A2 WO2010049678A2 (fr) 2010-05-06
WO2010049678A3 true WO2010049678A3 (fr) 2010-08-26

Family

ID=41820684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002554 WO2010049678A2 (fr) 2008-10-31 2009-10-27 Traitement de maladies utilisant de l’énergie

Country Status (1)

Country Link
WO (1) WO2010049678A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5645137B2 (ja) * 2009-11-11 2014-12-24 国立大学法人富山大学 食後過血糖改善剤、およびピロリジン型イミノ糖またはその塩
PT2655388T (pt) 2010-12-23 2016-09-06 Merck Sharp & Dohme Inibidores de glicosidase seletivos e as suas utilizações
CN102659787B (zh) * 2011-03-29 2015-04-01 中国科学院化学研究所 氟代多羟基吡咯里西啶及其制备方法与应用
EP2691407B1 (fr) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Inhibiteurs sélectifs de glycosidases et leurs utilisations
WO2014032185A1 (fr) * 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Inhibiteurs de glycosidases et leurs utilisations
EP2890678A4 (fr) * 2012-08-31 2016-01-27 Alectos Therapeutics Inc Inhibiteurs de glycosidases et leurs utilisations
WO2014032184A1 (fr) * 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Inhibiteurs de glycosidases et leurs utilisations
US9809537B2 (en) 2012-08-31 2017-11-07 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
RU2672873C2 (ru) 2012-10-31 2018-11-20 Алектос Терапьютикс Инк. Ингибиторы гликозидаз и их применения
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN105377266A (zh) 2013-04-18 2016-03-02 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
CN103265476B (zh) * 2013-05-16 2015-09-09 中国科学院化学研究所 氮杂糖季铵盐化合物及其制备方法与应用
GB201313440D0 (en) * 2013-07-29 2013-09-11 Phytoquest Ltd Characterization of rice
PT3233852T (pt) 2014-12-18 2020-09-10 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indóis como moduladores do recetor de estrogénio e suas utilizações
RU2766579C2 (ru) 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
EP3362055B1 (fr) 2015-10-15 2023-01-18 Boehringer Ingelheim International GmbH Inhibiteur de sglt-2 destiné à être utilisé dans le traitement d'une myopathie métabolique
CN105503687A (zh) * 2015-12-03 2016-04-20 广东药学院 具多元环的多羟基生物碱类化合物及其应用
CN105541854B (zh) * 2016-01-11 2018-04-13 中国科学院化学研究所 苦马豆素及其中间体的制备方法和苦马豆素衍生物及其制备方法和应用
KR102564647B1 (ko) 2018-06-21 2023-08-11 에프. 호프만-라 로슈 아게 3-((1R,3R)-1-(2,6-다이플루오로-4-((1-(3-플루오로프로필)아제티딘-3-일)아미노)페닐)-3-메틸-1,3,4,9-테트라하이드로-2H-피리도[3,4-b]인돌-2-일)-2,2-다이플루오로프로판-1-올의 고체 형태, 치환된 페닐 또는 피리딘일 잔기를 포함하는 융합된 삼환형 화합물의 제조 방법, 및 이의 사용 방법
GB201819759D0 (en) * 2018-12-04 2019-01-23 Phytoquest Ltd Bioactive phytochemicals in zizphus and guarana
CN110128315B (zh) * 2019-04-02 2021-08-20 中国科学院化学研究所 化合物及其制备方法与应用、糖苷酶抑制剂
CN115089578B (zh) * 2022-07-25 2023-08-25 山西医科大学 一种用于非酒精性脂肪肝病的化合物、组合物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009040A1 (fr) * 1995-09-08 1997-03-13 Novo Nordisk A/S 2-alkylpyrrolidines
WO1998050359A1 (fr) * 1997-05-06 1998-11-12 Novo Nordisk A/S Nouveaux composes heterocycliques
JP2000044589A (ja) * 1998-08-03 2000-02-15 Kikkoman Corp マルトオリゴ糖誘導体及びその用途
JP2001002648A (ja) * 1999-06-17 2001-01-09 Kikkoman Corp Ｎ−置換アゼパン誘導体及びそれらの塩
WO2004064715A2 (fr) * 2003-01-23 2004-08-05 M N L Pharma Limited Compositions immunomodulatrices
WO2006008493A1 (fr) * 2004-07-23 2006-01-26 Mnl Pharma Limited Synthèse des alcaloïdes polyhydroxylés
WO2009152665A1 (fr) * 2008-06-20 2009-12-23 湖南希尔天然药业有限公司 Composition pharmaceutique pour traiter le diabète

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009040A1 (fr) * 1995-09-08 1997-03-13 Novo Nordisk A/S 2-alkylpyrrolidines
WO1998050359A1 (fr) * 1997-05-06 1998-11-12 Novo Nordisk A/S Nouveaux composes heterocycliques
JP2000044589A (ja) * 1998-08-03 2000-02-15 Kikkoman Corp マルトオリゴ糖誘導体及びその用途
JP2001002648A (ja) * 1999-06-17 2001-01-09 Kikkoman Corp Ｎ−置換アゼパン誘導体及びそれらの塩
WO2004064715A2 (fr) * 2003-01-23 2004-08-05 M N L Pharma Limited Compositions immunomodulatrices
WO2006008493A1 (fr) * 2004-07-23 2006-01-26 Mnl Pharma Limited Synthèse des alcaloïdes polyhydroxylés
WO2009152665A1 (fr) * 2008-06-20 2009-12-23 湖南希尔天然药业有限公司 Composition pharmaceutique pour traiter le diabète

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANTIGNY ET AL: "Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR", CELL CALCIUM (EDINBURGH), CHURCHILL LIVINGSTONE MEDICAL JOURNALS, EDINBURGH, GB, vol. 43, no. 2, 19 January 2008 (2008-01-19), pages 175 - 183, XP022425997, ISSN: 0143-4160 *
BIJL NORA ET AL: "Reduction of Glycosphingolipid Biosynthesis Stimulates Biliary Lipid Secretion In Mice", HEPATOLOGY, vol. 49, no. 2, February 2009 (2009-02-01), pages 637 - 645, XP008120682, ISSN: 0270-9139 *
CASIROLA ET AL: "alpha-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 55, no. 6, 1 June 2006 (2006-06-01), pages 832 - 841, XP005437629, ISSN: 0026-0495 *
COX, TIMOTHY M. ET AL: "Medicinal use of iminosugars", IMINOSUGARS , 295-326. EDITOR(S): COMPAIN, PHILIPPE; MARTIN, OLIVIER R. PUBLISHER: JOHN WILEY & SONS LTD., CHICHESTER, UK. CODEN: 69KIVU; ISBN: 978-0-470-03391-3, 2007, XP008120616 *
KIMURA, MASAYASU ET AL: "Antihyperglycemic effects of N-containing sugars derived from mulberry leaves in streptozocin-induced diabetic mice", WAKAN IYAKUGAKU ZASSHI , 12(3), 214-19 CODEN: WIZAEL; ISSN: 1340-6302, 1995, XP008120663 *
KONG, WON-HO ET AL: "Antiobesity Effects and Improvement of Insulin Sensitivity by 1-Deoxynojirimycin in Animal Models", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY , 56(8), 2613-2619 CODEN: JAFCAU; ISSN: 0021-8561, 2008, XP008120627 *
MARTIN O: "Iminosugars: current and future therapeutic applications", ANNALES PHARMACEUTIQUES FRANCAISES, MASSON, PARIS, FR, vol. 65, no. 1, 1 January 2007 (2007-01-01), pages 5 - 13, XP008105411, ISSN: 0003-4509 *
NOREZ CAROLINE ET AL: "A Cystic Fibrosis Respiratory Epithelial Cell Chronically Treated by Miglustat Acquires a Non-Cystic Fibrosis-Like Phenotype", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 41, no. 2, 1 August 2009 (2009-08-01), pages 217 - 225, XP008111572, ISSN: 1044-1549 *

Also Published As

Publication number Publication date
WO2010049678A2 (fr) 2010-05-06

Similar Documents

Publication Publication Date Title
WO2010049678A3 (fr) Traitement de maladies utilisant de l’énergie
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
WO2009055331A3 (fr) Dérivés hétérocycliques bicycliques et leurs procédés d'utilisation
WO2007124461A8 (fr) Composés de glp-1
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
EP2361618A3 (fr) Compositions pour traiter ou prevenir l'obesite et les troubles de resistance a l'insuline
EP2120959A4 (fr) Procédés et compositions destinés au traitement de la résistance à l'insuline, du diabète et d'une dyslipidémie associée au diabète
WO2010008739A3 (fr) Agonistes des récepteurs gpr119 aryles et utilisations associées
EP1841781A4 (fr) Utilisation de l'il-22 pour le traitement de troubles metaboliques
WO2005103002A3 (fr) Nouveaux composes d'alcyne a effet antagoniste vis-a-vis de mch et medicaments contenant ces composes
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
WO2009051706A3 (fr) Composés peptidiques pour le traitement de l'obésité et de la résistance à l'insuline
EP2133091A3 (fr) Compositions renfermant des assemblages supramoléculaires pour le traitement du diabète
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
MX2020009811A (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico.
EP2036574A4 (fr) Préparation médicamenteuse destinée au traitement péroral de l'excès pondéral, du diabète sucré et de maladies accompagnées d'une perturbation de la tolérance du glucose
EP2579876A4 (fr) Traitement thérapeutique d'un syndrome métabolique, du diabète de type 2, de l'obésité ou de prédiabètes
WO2009143387A3 (fr) Modulation de l’expression de smrt
IL226386A0 (en) Medical treatment for metabolic syndrome, type 2 diabetes, obesity or pre-diabetes
HK1160681A1 (zh) 用於與代謝綜合征、心血管疾病和/或胰島素抗性相關的病症的診斷、預後、監測和治療追踪的體外方法
WO2009027106A3 (fr) Imagerie in vivo non invasive et procédés de traitement du diabète de type i
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
WO2007070355A3 (fr) Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09763990

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09763990

Country of ref document: EP

Kind code of ref document: A2